Anixa Biosciences (ANIX) Corporate presentation summary

Business overview and financials

• Clinical-stage company focused on developing first-in-class cancer therapies and vaccines.

• Maintains a capital-efficient model with $14M in cash and short-term investments as of January 31, 2026.

• Annual cash burn is approximately $5-7M, with no debt, warrants, or preferred stock.

• Strong insider buying and a clean capital table support financial stability.

Clinical pipeline and partnerships

• Pipeline includes CAR-T therapy for ovarian cancer, breast cancer vaccine, and preclinical vaccines for ovarian, lung, colon, and prostate cancers.

• Key partnerships with Moffitt Cancer Center, The Wistar Institute, Cleveland Clinic, and NIH.

• Programs leverage partner infrastructure to minimize overhead and enable multiple projects.

• Out-licensing or selling programs to pharma partners for late-stage development and commercialization.

CAR-T program for ovarian cancer

• Lira-cel targets FSHR, a receptor found primarily on ovarian and tumor blood vessels.

• Dual mechanism: direct tumor cell killing and anti-angiogenesis by destroying tumor vasculature.

• Intraperitoneal delivery enhances safety and efficacy by localizing treatment and reducing systemic side effects.

• Phase 1 dose-escalation trial ongoing in recurrent/chemoresistant ovarian cancer.

• Early patient data show survival beyond median life expectancy in several cohorts.